Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill KQB198 tested for tough blood cancers

NCT ID NCT06645886

Disease control Sponsor: Kumquat Biosciences Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new oral drug called KQB198, alone or with another drug (dasatinib), in 13 adults with advanced blood cancers that have not responded to prior treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants take the drug daily and visit the clinic regularly for monitoring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
KQB198 (oral drug) and dasatinib (oral drug)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced blood cancers that have stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1) trial with only 13 participants, so it is mainly checking safety and dosing. It is too small and early to know if the drug will work or be safe for wider use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

13 people

The number who actually took part.

Started

Dec 2024

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adequate organ function Part 1 and Part 2, Cohort B Participants Only: • Ph+ CML in chronic phase who have been previously treated with at least 2 different tyrosine kinase inhibitors (TKIs) and are relapsed from or intolerant to those TKIs and ineligible for alternative therapeutic options likely to produce clinical benefit as determined by the investigator. Part 2, Cohort A Participants Only: • Participants with Ph+ CML in chronic phase who are on dasatinib prior to study entry and have a warning or failure to dasatinib as determined by the investigator per ELN 2020 guidelines Exclusion Criteria: * CML in accelerated or blast phase * Prior therapy with a similar mechanism of action to KQB198 * History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow * History of interstitial lung disease * Cardiac abnormalities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adult Hematologic malignancies

Contacts and locations

Locations

  • AP-HM - Hopital de la Timone

    Marseille, 13005, France

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Lombardy, 20162, Italy

  • Aidport Sp. z o.o.

    Poznan, Greater Poland Voivodeship, 60-185, Poland

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • CHRU de Tours - Hopital Bretonneau

    Tours, Centre-Val de Loire, 37044, France

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii

    Gdansk, Pomeranian Voivodeship, 80-214, Poland

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

    Milan, Milan, Lombardy, 20122, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Rome, Lazio, 00168, Italy

  • Hammersmith Hospital

    London, Greater London, W12 0HS, United Kingdom

  • Hospital Regional Universitario de Malaga

    Málaga, Andalusia, 29010, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, 28041, Spain

  • Hospital Universitario La Paz

    Madrid, Madrid, 28046, Spain

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola

    Bologna, Bologna, 40138, Italy

  • Institut Catala d'Oncologia - L'Hospitalet

    L'Hospitalet de Llobregat, Catalonia, 08908, Spain

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Medizinische Hochschule Hannover (MHH)

    Hanover, Lower Saxony, 30625, Germany

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Nottingham University Hospitals

    Nottingham, Nottinghamshire, NG5 1PB, United Kingdom

  • Oncology Hematology Cincinnati

    Cincinnati, Ohio, 45236, United States

  • Pratia Onkologia Katowice

    Katowice, Silesian Voivodeship, 40-519, Poland

  • Sarah Cannon Research Institute (SCRI) - Transplant and Cellular Therapy Operations

    Nashville, Tennessee, 37203, United States

  • Stichting Radboud Universitair Medisch Centrum

    Nijmegen, Gelderland, 6525, Netherlands

  • Texas Oncology Austin Central

    Austin, Texas, 78731, United States

  • Universitaetsklinikum Jena

    Jena, Thuringia, 07747, Germany

  • University of California, San Francisco (UCSF)

    San Francisco, California, 94143, United States

  • Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii

    Gdansk, Pomeranian Voivodeship, 80-952, Poland

  • Virginia Cancer Specialists

    Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.